文献速递妇科

复发性上皮性卵巢癌的三次肿瘤细胞减灭术:一项MITO多中心回顾性研究

Tertiary cytoreductive surgery in recurrent epithelial ovarian cancer: A multicentre MITO retrospective study.
PubMed 文献 · Gynecol Oncol · 2017-07-15

在MITO协作组内开展5年观察期的多中心回顾性研究,纳入103例无治疗间期≥6个月后接受三次肿瘤细胞减灭术的复发性上皮性卵巢癌患者。完全细胞减灭者71例(68.9%),术后严重并发症发生率9.7%,术后60天内无死亡病例。完全减灭组中位总生存43个月(95%CI 31-58),优于残留肿瘤组33个月(95%CI 28-46;P<0.001)。

要点

  • 完全三次细胞减灭是生存最强预测因素,中位总生存43 vs 33个月(P<0.001)。
  • 单发病灶与ECOG 0体能状态是完成完全细胞减灭的独立预测因素。
  • 初次诊断FIGO I-II期、仅腹膜后复发及初次诊断≥3年后行三次手术亦与生存相关。

核心结论

  • 在三次肿瘤细胞减灭术背景下,术后无残留病灶仍是首要目标,可带来显著生存获益且并发症可接受。
  • 精准的患者选择对获得完全细胞减灭的最佳机会至关重要。

研究设计与样本

  • MITO协作组内开展的多中心回顾性研究,观察期为5年,共纳入103例无治疗间期≥6个月后接受三次肿瘤细胞减灭术的复发性上皮性卵巢癌患者。

主要发现

  • 完全细胞减灭71例(68.9%),术后严重并发症发生率9.7%,术后60天内无死亡病例。
  • 完全三次细胞减灭组中位总生存43个月(95%CI 31-58),残留肿瘤组33个月(95%CI 28-46),差异有统计学意义(P<0.001)。
  • 多因素分析显示完全三次细胞减灭是最强生存预测因素,其后依次为初次诊断FIGO I-II期、仅腹膜后复发、初次诊断≥3年后行三次手术。
  • 多因素调整后,单发病灶与ECOG 0体能状态是完成完全细胞减灭仅有的显著预测因素。

关键数值与推荐

  • 完全细胞减灭定义:术后无残留病灶,本研究中71例(68.9%)达到。
  • 生存预测因素:完全三次细胞减灭、初次诊断FIGO I-II期、仅腹膜后复发、初次诊断≥3年后行三次手术。
  • 完全细胞减灭预测因素:单发病灶、ECOG 0体能状态。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To evaluate the impact of tertiary cytoreductive surgery (TCS) on survival in recurrent epithelial ovarian cancer (EOC), and to determine predictors of complete cytoreduction. METHODS: A multi-institutional retrospective study was conducted within the MITO Group on a 5-year observation period. RESULTS: A total of 103 EOC patients with a ≥6month treatment-free interval (TFI) undergoing TCS were included. Complete cytoreduction was achieved in 71 patients (68.9%), with severe post-operative complications in 9.7%, and no cases of mortality within 60days from surgery. Multivariate analysis identified the complete tertiary cytoreduction as the most potent predictor of survival followed by FIGO stage I-II at initial diagnosis, exclusive retroperitoneal recurrence, and TCS performed ≥3years after primary diagnosis. Patients with complete tertiary cytoreduction had a significantly longer overall survival (median OS: 43months, 95% CI 31-58) compared to those with residual tumor (median OS: 33months, 95% CI 28-46; p<0.001). After multivariate adjustment the presence of a single lesion and good (ECOG 0) performance status were the only significant predictors of complete surgical cytoreduction. CONCLUSIONS: This is the only large multicentre study published so far on TCS in EOC with ≥6month TFI. The achievement of postoperative no residual disease is confirmed as the primary objective also in a TCS setting, with significant survival benefit and acceptable morbidity. Accurate patient selection is of utmost importance to have the best chance of complete cytoreduction.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Falcone F, Scambia G, Benedetti Panici P, et al. Tertiary cytoreductive surgery in recurrent epithelial ovarian cancer: A multicentre MITO retrospective study. Gynecol Oncol. 2017. PMID: 28716306. doi:10.1016/j.ygyno.2017.07.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。